辅助放疗对pT2N0口腔鳞状细胞癌复发结局的影响:倾向性评分匹配生存分析
本研究基于前瞻性数据库纳入2015至2023年400例pT2N0口腔鳞状细胞癌患者,其中226例单纯手术、174例接受辅助放疗,经1:1倾向性评分匹配生成107对。匹配后3年无病生存率单纯手术组78.3%、手术加放疗组82.1%(p=0.41),辅助放疗与DFS改善无关(HR 0.81,95%CI 0.48-1.30;p=0.43)。
要点
- pT2N0口腔鳞癌中辅助放疗未显著改善3年DFS
- 匹配后3年DFS:单纯手术78.3% vs 手术加放疗82.1%
- 辅助放疗与DFS无关(HR 0.81,95%CI 0.48-1.30)
核心结论
- 在倾向性评分匹配队列中,辅助放疗与pT2N0口腔鳞状细胞癌3年DFS改善无关。
研究设计与样本
- 回顾性队列研究,数据来自前瞻性维护数据库,纳入2015至2023年pT2N0口腔鳞状细胞癌患者。
- 共400例 eligible 患者,226例单纯手术、174例接受辅助放疗,经1:1最近邻倾向性评分匹配生成107对。
- 匹配变量包括年龄、肿瘤大小、浸润深度、神经周围侵犯、淋巴血管侵犯、切缘距离、肿瘤亚部位、组织学分级及双侧颈清扫状态。
主要发现
- 匹配后3年DFS单纯手术组为78.3%,手术加放疗组为82.1%(p=0.41)。
- 辅助放疗与DFS无显著关联(HR 0.81,95%CI 0.48-1.30;p=0.43)。
临床怎么用
- 对于pT2N0口腔鳞状细胞癌,辅助放疗不应常规用于改善无病生存,需结合个体风险因素综合决策。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of adjuvant radiotherapy in pT2N0 oral squamous cell carcinoma (OSCC) remains uncertain. We evaluated its impact on disease-free survival (DFS) using propensity score matching. METHODS: Patients with pT2N0 OSCC treated between 2015 and 2023 were identified from a prospectively maintained database. One-to-one nearest-neighbor propensity score matching was performed using age, tumor size, depth of invasion, perineural invasion, lymphovascular invasion, margin distance, tumor subsite, histological grade, and bilateral neck dissection status. Three-year DFS was analyzed using Kaplan-Meier methods and Cox regression. RESULTS: Among 400 eligible patients, 226 underwent surgery alone, and 174 received adjuvant radiotherapy. Propensity score matching generated 107 matched pairs. Three-year DFS was 78.3% for surgery alone and 82.1% for surgery plus radiotherapy (p = 0.41). Adjuvant radiotherapy was not associated with improved DFS (HR 0.81, 95% CI 0.48-1.30; p = 0.43). CONCLUSIONS: In this propensity score-matched cohort, adjuvant radiotherapy was not associated with improved 3-year DFS in pT2N0 OSCC.
引用
- Nemade H, Thaduri A, Gondi JT, et al. Impact of Adjuvant Radiotherapy on Recurrence Outcomes in pT2N0 Oral Squamous Cell Carcinoma: A Propensity Score-Matched Survival Analysis. Head Neck. 2026. PMID: 42425923. doi:10.1002/hed.70391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。